Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
12/01/2026 12:40
Jan 12 (Reuters) - Cabaletta Bio Inc CABA.O: IND AMENDMENT CLEARANCE OBTAINED FOR CLINICAL MANUFACTURING OF RESE-CEL FROM CABALETTA BIO USING CELLARES' AUTOMATED PLATFORMS Source text: ID:nBw7rLTWva Further company coverage: CABA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsBrief: Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cabaletta Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cabaletta Bio Q2 net loss widens as R&D costs rise
Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 37 cents a share - Earnings Preview